Literature DB >> 19950257

Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.

Pravitt Gourh1, Sandeep K Agarwal, Dipal Divecha, Shervin Assassi, Gene Paz, Rajpreet K Arora-Singh, John D Reveille, Sanjay Shete, Maureen D Mayes, Frank C Arnett, Filemon K Tan.   

Abstract

OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs. Dysregulation of the immune system, including the Th1/Th2 cytokine balance, is central to the pathogenesis of SSc. This study was undertaken to investigate the hypothesis that single-nucleotide polymorphisms (SNPs) in TBX21 and STAT4, both of which are critical transcription factors that regulate the Th1/Th2 balance, are associated with SSc susceptibility.
METHODS: We tested SNPs in TBX21 and STAT4 for association with SSc in 2 independent cohorts, the SSc Registry cohort (880 SSc cases and 507 controls) and the University of Texas SSc cohort (522 cases and 531 controls). Additional white control genotypes were obtained from public repositories. We also investigated for gene-gene interactions. Plasma cytokines and whole blood gene expression profiles were examined to determine functional effects of these SNPs.
RESULTS: Multiple SNPs in TBX21 and STAT4 were found to be associated with SSc. In a combined analysis of 902 SSc patients and 4,745 controls, TT genotyping of the TBX21 rs11650354 variant revealed a recessive pattern for disease susceptibility (Pcorr=1.4x10(-15), odds ratio 3.37, 95% confidence interval 2.4-4.6). In an analysis of 1,039 SSc patients and 3,322 controls, the A allele of the STAT4 variant rs11889341 was associated with increased SSc susceptibility in a dominant pattern (Pcorr=2.4x10(-5), odds ratio 1.29, 95% confidence interval 1.2-1.5). Furthermore, we identified gene-gene interaction among the TBX21 and STAT4 variants, such that the STAT4 genotype increased the risk of SSc only in the TBX21 CC genotype group. SSc patients carrying the TBX21 CC genotype had higher interleukin-6 (IL-6) and tumor necrosis factor alpha levels, and those with the TT genotype had elevated IL-2, IL-5, IL-4, and IL-13 (Th2) levels, compared with controls. Whole blood expression profiles revealed dysregulation of type I interferon pathways in the CC group and T cell pathways in the TT group of the TBX21 SNP.
CONCLUSION: The present results, from studies of 2 independent cohorts, indicate that SNPs in TBX21 and STAT4 contribute uniquely and interactively to SSc susceptibility, leading to altered cytokine balance and immune dysregulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19950257      PMCID: PMC2998060          DOI: 10.1002/art.24958

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  51 in total

1.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.

Authors:  R Giacomelli; P Cipriani; R Lattanzio; M Di Franco; M Locanto; I Parzanese; A Passacantando; A Ciocci; G Tonietti
Journal:  Clin Exp Immunol       Date:  1997-04       Impact factor: 4.330

2.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration.

Authors:  M B Kahaleh; E C LeRoy
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

3.  HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis).

Authors:  F K Tan; D N Stivers; F C Arnett; R Chakraborty; R Howard; J D Reveille
Journal:  Tissue Antigens       Date:  1999-01

4.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis.

Authors:  C Mavalia; C Scaletti; P Romagnani; A M Carossino; A Pignone; L Emmi; C Pupilli; G Pizzolo; E Maggi; S Romagnani
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

5.  Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis.

Authors:  F C Arnett; J D Reveille; R Goldstein; K M Pollard; K Leaird; E A Smith; E C Leroy; M J Fritzler
Journal:  Arthritis Rheum       Date:  1996-07

6.  Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.

Authors:  F C Arnett; R F Howard; F Tan; J M Moulds; W B Bias; E Durban; H D Cameron; G Paxton; T J Hodge; P E Weathers; J D Reveille
Journal:  Arthritis Rheum       Date:  1996-08

7.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population.

Authors:  F K Tan; D N Stivers; M W Foster; R Chakraborty; R F Howard; D M Milewicz; F C Arnett
Journal:  Arthritis Rheum       Date:  1998-10

Review 10.  HLA and autoimmunity in scleroderma (systemic sclerosis).

Authors:  F C Arnett
Journal:  Int Rev Immunol       Date:  1995       Impact factor: 5.311

View more
  43 in total

Review 1.  Unraveling the genetic component of systemic sclerosis.

Authors:  José Ezequiel Martín; Lara Bossini-Castillo; Javier Martín
Journal:  Hum Genet       Date:  2012-01-05       Impact factor: 4.132

2.  Association between gastric cancer and -1993 polymorphism of TBX21 gene.

Authors:  Le-Hui Zhang; Qin Li; Peng Li; Sheng-Tao Zhu; Jing Wang; Hong-Li Yang; Chang-Qing Xu; Xiu-Hua Guo
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

3.  Identification of an Association of TNFAIP3 Polymorphisms With Matrix Metalloproteinase Expression in Fibroblasts in an Integrative Study of Systemic Sclerosis-Associated Genetic and Environmental Factors.

Authors:  Peng Wei; Yang Yang; Xinjian Guo; Nainan Hei; Syeling Lai; Shervin Assassi; Mengyuan Liu; Filemon Tan; Xiaodong Zhou
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 4.  A unifying hypothesis for scleroderma: identifying a target cell for scleroderma.

Authors:  William M Mahoney; Jo Nadine Fleming; Stephen M Schwartz
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 6.  Genetics of systemic sclerosis.

Authors:  Lara Bossini-Castillo; Elena López-Isac; Maureen D Mayes; Javier Martín
Journal:  Semin Immunopathol       Date:  2015-06-02       Impact factor: 9.623

7.  Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.

Authors:  Lenny van Bon; Alsya J Affandi; Jasper Broen; Romy B Christmann; Renoud J Marijnissen; Lukasz Stawski; Giuseppina A Farina; Giuseppina Stifano; Allison L Mathes; Marta Cossu; Michael York; Cindy Collins; Mark Wenink; Richard Huijbens; Roger Hesselstrand; Tore Saxne; Mike DiMarzio; Dirk Wuttge; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Maureen Mayes; Yanhui Deng; Joost P H Drenth; Jacqueline de Graaf; Martin den Heijer; Cees G M Kallenberg; Marc Bijl; Arnoud Loof; Wim B van den Berg; Leo A B Joosten; Vanessa Smith; Filip de Keyser; Rafaella Scorza; Claudio Lunardi; Piet L C M van Riel; Madelon Vonk; Waander van Heerde; Stephan Meller; Bernhard Homey; Lorenzo Beretta; Mark Roest; Maria Trojanowska; Robert Lafyatis; Timothy R D J Radstake
Journal:  N Engl J Med       Date:  2013-12-18       Impact factor: 91.245

Review 8.  The genetics of scleroderma: looking into the postgenomic era.

Authors:  Maureen D Mayes
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

Review 9.  Unfolding the pathogenesis of scleroderma through genomics and epigenomics.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  J Autoimmun       Date:  2017-05-16       Impact factor: 7.094

Review 10.  Genetics, Epigenetics, and Genomics of Systemic Sclerosis.

Authors:  Gloria Salazar; Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2015-05-20       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.